Payoneer Global Inc. (PAYO)
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Investigation
11/22/2021
Initial Lawsuit
04/21/2022
Lawsuit Progression
06/21/2022
Investors investigation focused on statements made prior to and during the merger with the special purpose acquisition (SPAC) VPC Impact Acquisition Holdings (traded “VIHAU”, “VIH”, and “VIHAW”) regarding the misclassification of certain shares, defective internal controls & errors in financial statements leading to the restatement of financials.
11/22/2021
Bakkt discloses that its management “has re-evaluated the application of ASC 480-10-S99-3A to the accounting classification of the Class A ordinary shares . . . of VPC Acquisition Impact Holdings (“VIH”)” prior to the completion of the business combination “and has identified errors in the historical financial statements of VIH . . . the Company has determined that it is appropriate to restate certain of VIH’s condensed consolidated financial statements.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$17.02 | $19.72 | $-2.7 | -13.69% |
This is a federal securities class action on behalf of a class consisting of all persons and entities other than defendants that purchased or otherwise acquired:
(a) Bakkt securities between March 31, 2021 and November 19, 2021, both dates inclusive; and/or
(b) Bakkt Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the business combination between Bakkt Holdings, Inc. f/k/a VPC Impact Acquisition Holdings and Bakkt Holdings, LLC completed on or about October 15, 2021.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) the company had defective financial controls;
(ii) as a result, there were errors in the company’s financial statements related to the misclassification of certain shares issued prior to the business combination;
(iii) accordingly, the company would need to restate certain of its financial statements;
(iv) the company downplayed the true scope and severity of these issues;
(v) the company overstated its remediation of its defective financial controls; and
(vi) as a result, the offering documents and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
The lead plaintiff deadline has passed, we will update this page as the lawsuit progresses.
Last event retrieved on 10/07/2022.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.